US Patent Issued to Blueprint Medicines on Aug. 4 for "Synthetic methods and intermediates for producing compounds for treating KIT- and PDGFRA-mediated diseases" (French, American, Swiss Inventors)

ALEXANDRIA, Va., Aug. 5 -- United States Patent no. 12,698,290, issued on Aug. 4, was assigned to Blueprint Medicines Corp. (Cambridge, Mass.).

"Synthetic methods and intermediates for producing compounds for treating KIT- and PDGFRA-mediated diseases" was invented by Gilles Caillot (Saint Leu d'Esserent, France), Khalid Diker (Saint Leu d'Esserent, France), Brian Heinrich (Cambridge, Mass.), Christopher Lee (Cambridge, Mass.), Hui Li (Cambirdge, Mass.), Baptiste Tournade (Saint Leu d'Esserent, France) and Andreas Wagner (Dottikon, Switzerland).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides methods and intermediates for making Compound A or a pharmaceutical salt thereof, and/or...